Results 161 to 170 of about 206,101 (297)

Computational Medicinal Chemistry

Future Medicinal Chemistry, 2011
openaire   +2 more sources

Loss of proton‐sensing TDAG8 increases tumor progression in mouse models of colon cancer

Molecular Oncology, EarlyView.
Loss of the pH‐sensing receptor TDAG8 accelerates colorectal cancer progression in mice. Animals lacking TDAG8 expression had increased tumor growth, DNA damage, and recruitment of tumor‐associated immune cells, including macrophages, neutrophils, and monocytes.
Ermanno Malagola, Yasmine Illi, Anna Bircher, Marijn Wilmink, Rachele F. Malagutti, Solenn Ottié, Cordelia Schuler, Pedro A. Ruiz, Cheryl de Vallière, Klaus Seuwen, Gerhard Rogler, Martin Hausmann   +11 more
wiley   +1 more source

Medicinal Chemistry: Abstracts 280-357

CHIMIA, 2012
doaj   +1 more source

Approach to Heterospirocycles for Medicinal Chemistry. [PDF]

Org Lett
Rodríguez-Arias C, Miguélez R, Holota Y, Mykhailiuk PK, Barrio P.   +4 more
europepmc   +1 more source

Medicinal Chemistry: Abstracts 76-120

CHIMIA, 2008
doaj   +1 more source

The many facets of sustainability in medicinal chemistry: our personal experience. [PDF]

RSC Med Chem
Martinengo B, Diamanti E, Uliassi E, Bolognesi ML.   +3 more
europepmc   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Medicinal Chemistry: Abstracts 56-105

CHIMIA, 2009
doaj   +1 more source

Biphenyl as a Privileged Structure in Medicinal Chemistry: Advances in Anti-Infective Drug Discovery. [PDF]

Molecules
Gandi MO, França RRF, Castelo-Branco FS, Boechat N.   +3 more
europepmc   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source